Literature DB >> 18187039

Caspase cleavage of the MET receptor generates an HGF interfering fragment.

Julien Deheuninck1, Bénédicte Foveau, Gautier Goormachtigh, Catherine Leroy, Zongling Ji, David Tulasne, Véronique Fafeur.   

Abstract

The MET tyrosine kinase receptor activated by its ligand HGF/SF, induces several cellular responses, including survival. Nonetheless, the MET receptor is cleaved in stress conditions by caspases within its intracellular region, generating a 40kDa fragment, p40 MET, with pro-apoptotic properties. Here, we established that this cleavage splits the receptor at the juxtamembrane ESVD site, causing the concomitant generation of p100 MET, corresponding to the entire extracellular region of the MET receptor still spanning the membrane. This fragment is able to bind HGF/SF and to prevent HGF-dependent signaling downstream of full MET, demonstrating its function as a decoy receptor.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18187039     DOI: 10.1016/j.bbrc.2007.12.177

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  12 in total

1.  Down-regulation of the met receptor tyrosine kinase by presenilin-dependent regulated intramembrane proteolysis.

Authors:  Bénédicte Foveau; Frédéric Ancot; Catherine Leroy; Annalisa Petrelli; Karina Reiss; Valérie Vingtdeux; Silvia Giordano; Véronique Fafeur; David Tulasne
Journal:  Mol Biol Cell       Date:  2009-03-18       Impact factor: 4.138

2.  Prognostic implication of serum hepatocyte growth factor in stage II/III breast cancer patients who received neoadjuvant chemotherapy.

Authors:  Hyori Kim; Jeonghwan Youk; Yaewon Yang; Tae-Yong Kim; Ahrum Min; Hye-Seon Ham; Seongcheol Cho; Kyung-Hun Lee; Bhumsuk Keam; Sae-Won Han; Do-Youn Oh; Han Suk Ryu; Wonshik Han; In Ae Park; Tae-You Kim; Dong-Young Noh; Seock-Ah Im
Journal:  J Cancer Res Clin Oncol       Date:  2015-11-18       Impact factor: 4.553

3.  Anti-apoptotic role of caspase-cleaved GAB1 adaptor protein in hepatocyte growth factor/scatter factor-MET receptor protein signaling.

Authors:  Arnaud Le Goff; Zongling Ji; Bérénice Leclercq; Roland P Bourette; Alexandra Mougel; Cateline Guerardel; Yvan de Launoit; Jérôme Vicogne; Gautier Goormachtigh; Véronique Fafeur
Journal:  J Biol Chem       Date:  2012-08-22       Impact factor: 5.157

Review 4.  Caspases and kinases in a death grip.

Authors:  Manabu Kurokawa; Sally Kornbluth
Journal:  Cell       Date:  2009-09-04       Impact factor: 41.582

5.  Necrosis- and apoptosis-related Met cleavages have divergent functional consequences.

Authors:  R Montagne; M Berbon; L Doublet; N Debreuck; A Baranzelli; H Drobecq; C Leroy; N Delhem; H Porte; M-C Copin; E Dansin; A Furlan; D Tulasne
Journal:  Cell Death Dis       Date:  2015-05-21       Impact factor: 8.469

6.  Caspase-mediated proteolysis of the sorting nexin 2 disrupts retromer assembly and potentiates Met/hepatocyte growth factor receptor signaling.

Authors:  Catherine M Duclos; Audrey Champagne; Julie C Carrier; Caroline Saucier; Christine L Lavoie; Jean-Bernard Denault
Journal:  Cell Death Discov       Date:  2017-01-23

7.  MET receptor variant R970C favors calpain-dependent generation of a fragment promoting epithelial cell scattering.

Authors:  Rémi Montagne; Anne Baranzelli; Ghaffar Muharram; Leroy Catherine; Marie Lesaffre; Audrey Vinchent; Zoulika Kherrouche; Elisabeth Werkmeister; Alexis B Cortot; David Tulasne
Journal:  Oncotarget       Date:  2017-02-14

Review 8.  c-Met expression and activity in urogenital cancers - novel aspects of signal transduction and medical implications.

Authors:  Ralf Hass; Susanne Jennek; Yuanyuan Yang; Karlheinz Friedrich
Journal:  Cell Commun Signal       Date:  2017-02-17       Impact factor: 5.712

9.  A multi-factor model for caspase degradome prediction.

Authors:  Lawrence J K Wee; Joo Chuan Tong; Tin Wee Tan; Shoba Ranganathan
Journal:  BMC Genomics       Date:  2009-12-03       Impact factor: 3.969

10.  Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib.

Authors:  Gang Chen; Alfiah Noor; Peter Kronenberger; Erik Teugels; Ijeoma Adaku Umelo; Jacques De Grève
Journal:  PLoS One       Date:  2013-03-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.